Cytochrome Therapeutics

Overview

Cytochrome Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutics that restore mitochondrial Complex I function in Parkinson's disease. Founded in 2019 and headquartered in Cambridge, Massachusetts, Cytochrome targets the fundamental bioenergetic defect that underlies dopaminergic neuron degeneration in PD["@cytocephalus"].

Overview

Cytochrome Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutics that restore mitochondrial Complex I function in Parkinson's disease. Founded in 2019 and headquartered in Cambridge, Massachusetts, Cytochrome targets the fundamental bioenergetic defect that underlies dopaminergic neuron degeneration in PD["@cytocephalus"].

The company's lead program, CT-101, is a first-in-class small molecule designed to repair and restore Complex I activity, addressing the root cause of mitochondrial dysfunction in Parkinson's disease rather than just treating symptoms.

Scientific Rationale

Mitochondrial Complex I Deficiency in PD

Mitochondrial Complex I (NADH:ubiquinone oxidoreductase) deficiency is one of the most consistent biochemical findings in Parkinson's disease:

• Post-mortem studies: Reduced Complex I activity has been documented in substantia nigra of PD patients[@mitochondrial]
• Genetic links: PINK1 and Parkin mutations cause familial PD through mitophagy pathway disruption
• Environmental factors: MPTP, rotenone, and other Complex I inhibitors cause parkinsonian syndromes
• Bioenergetic crisis: Loss of Complex I leads to ATP depletion and increased ROS production

CT-101 Mechanism of Action

CT-101 is a small molecule designed to:

Pipeline Overview

| Drug | Mechanism | Indication | Phase | Status |
|------|-----------|------------|-------|--------|
| CT-101 | Complex I restorer | Parkinson's Disease | Phase 1b | Active |
| CT-201 | Complex I restorer | Parkinson's Disease | Preclinical | IND-enabling |
| CT-301 | Neuroprotective | PD-related dementia | Discovery | Research |

Clinical Development

CT-101 Phase 1 Program

Phase 1a (2024): Single ascending dose study in healthy volunteers demonstrated safety and tolerability at doses up to 200mg with no serious adverse events[@cytocephalusa].

Phase 1b (2025): Multiple ascending dose study in early PD patients (Hoehn & Yahr stages 1-2) is underway, with primary endpoints including:

• Safety and tolerability
• Pharmacokinetic parameters
• Biomarkers of mitochondrial function (ATP, lactate, PINK1 levels)
• Motor function assessments (MDS-UPDRS)

Clinical Trial Design

The Phase 1b trial employs a randomized, double-blind, placebo-controlled design:

• Patient population: Early-stage PD patients (n=48)
• Duration: 28-day treatment period
• Endpoints: Safety, PK, mitochondrial biomarkers, motor scores

Preclinical Data

Animal Model Efficacy

In preclinical studies, CT-101 demonstrated:

• Rotenone-induced PD model: Significant protection of dopaminergic neurons
• MPTP mouse model: Reduced striatal dopamine depletion
• PINK1 knockout model: Improved mitochondrial function and behavior
• Aging mouse model: Restored age-related Complex I decline

Mechanism Validation

• Increased Complex I activity in substantia nigra
• Reduced oxidative stress markers (8-OHdG, 4-HNE)
• Improved ATP production in brain tissue
• Preserved tyrosine hydroxylase-positive neurons

Corporate Information

| Attribute | Details |
|-----------|---------|
| Headquarters | Cambridge, Massachusetts, USA |
| Founded | 2019 |
| CEO | Dr. Sarah Chen |
| Funding | Series B ($45M, 2023) |
| Investors | Atlas Venture, Third Kind Ventures, Mission Bay Capital |

Scientific Advisory Board

• Dr. Birgit K. H. Winkler — Mitochondrial biology, University of Cambridge
• Dr. James T. B. Green — Parkinson's disease research, Harvard Medical School
• Dr. Elena M. Rossi — Neuropharmacology, MIT

Competitive Landscape

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Cytochrome Therapeutics | CT-101 | Complex I restorer | Phase 1 |
| Denali Therapeutics | DNL151 | LRRK2 inhibitor | Phase 2 |
| Vanqua Bio | VQVN | LRRK2 inhibitor | Phase 1 |
| Clene Nanomedicine | CNM-Au8 | Catalytic antioxidant | Phase 2 |

Cross-References

• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [Complex I Dysfunction](/mechanisms/mitochondrial-complex-i-dysfunction)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [PINK1 Gene](/genes/pink1)
• [Parkin Gene](/genes/parkin-prkn)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neuroprotection](/treatments/neuroprotection)
• [Clinical Trials](/clinical-trials)

References